Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
Add more filters










Publication year range
1.
Mol Neurobiol ; 2024 Apr 15.
Article in English | MEDLINE | ID: mdl-38619743

ABSTRACT

Glioblastoma (GBM) is the highest grade of glioma for which no effective therapy is currently available. Despite extensive research in diagnosis and therapy, there has been no significant improvement in GBM outcomes, with a median overall survival continuing at a dismal 15-18 months. In recent times, glioblastoma stem cells (GSCs) have been identified as crucial drivers of treatment resistance and tumor recurrence, and GBM therapies targeting GSCs are expected to improve patient outcomes. We used a multistep in silico screening strategy to identify repurposed candidate drugs against selected therapeutic molecular targets in GBM with potential to concomitantly target GSCs. Common differentially expressed genes (DEGs) were identified through analysis of multiple GBM and GSC datasets from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA). For identification of target genes, we selected the genes with most significant effect on overall patient survival. The relative mRNA and protein expression of the selected genes in TCGA control versus GBM samples was also validated and their cancer dependency scores were assessed. Drugs targeting these genes and their corresponding proteins were identified from LINCS database using Connectivity Map (CMap) portal and by in silico molecular docking against each individual target using FDA-approved drug library from the DrugBank database, respectively. The molecules thus obtained were further evaluated for their ability to cross blood brain barrier (BBB) and their likelihood of resulting in drug resistance by acting as p-glycoprotein (p-Gp) substrates. The growth inhibitory effect of these final shortlisted compounds was examined on a panel of GBM cell lines and compared with temozolomide through the drug sensitivity EC50 values and AUC from the PRISM Repurposing Secondary Screen, and the IC50 values were obtained from GDSC portal. We identified RPA3, PSMA2, PSMC2, BLVRA, and HUS1 as molecular targets in GBM including GSCs with significant impact on patient survival. Our results show GSK-2126458/omipalisib, linifanib, drospirenone, eltrombopag, nilotinib, and PD198306 as candidate drugs which can be further evaluated for their anti-tumor potential against GBM. Through this work, we identified repurposed candidate therapeutics against GBM utilizing a GSC inclusive targeting approach, which demonstrated high in vitro efficacy and can prospectively evade drug resistance. These drugs have the potential to be developed as individual or combination therapy to improve GBM outcomes.

2.
Biochim Biophys Acta Gen Subj ; 1867(12): 130472, 2023 12.
Article in English | MEDLINE | ID: mdl-37788726

ABSTRACT

FABP3 belongs to a large family of cytoplasmic fatty acid binding proteins that are expressed in a tissue-specific manner. It is predominantly expressed in breast, muscle and heart. During our exploratory studies on the role of FABP3 in tumorigenesis and our consequent attempts to study the molecular mechanism responsible for the oncogenic potential of FABP3, we came across an unexpected role of FABP3 as an anti-bacterial protein. Presence of the protein was detected in culture media of cell lines stably over-expressing human FABP3. Conditioned medium from these FABP3 over-expressing cells exerted a distinct anti-bacterial activity against E. coli. Our results indicate that binding of FABP3 to the bacterial cell surface contributes to its anti-bacterial activity. Incubation of E. coli bacterial cells with FABP3 protein led to disruption of the physical integrity of bacterial cell membrane causing leakage of cellular components. Further, in silico analysis predicted strong binding of FABP3 to the antibiotic binding sites on the bacterial ribosome. Interestingly, we found that FABP3 is a naturally occurring secretory protein present in milk in abundance as confirmed by western blot and ELISA. Thus, our experimental data together with in silico analysis suggests that FABP3 is secreted in milk, has an anti-bacterial function, shows activity against E. coli by disrupting bacterial membrane and targeting the ribosome, and may play a protective role against bacterial infection in newborns.


Subject(s)
Escherichia coli , Fatty Acid-Binding Proteins , Infant, Newborn , Humans , Escherichia coli/metabolism , Fatty Acid-Binding Proteins/metabolism , Fatty Acid Binding Protein 3
3.
Bioorg Chem ; 118: 105464, 2022 01.
Article in English | MEDLINE | ID: mdl-34785441

ABSTRACT

A series of imido-heterocycle compounds were designed, synthesized, characterized, and evaluated for the anticancer potential using breast (MCF-7 and MDA-MB-231), pancreatic (PANC-1), and colon (HCT-116 and HT-29) cancer cell lines and normal cells, while normal cells showed no toxicity. Among the screened compounds, 4h exhibited the best anticancer potential with IC50 values ranging from 1 to 5.5 µM. Compound 4h caused G2/M phase arrest and apoptosis in all the cell lines except MDA-MB-231 mammosphere formation was inhibited. In-vitro enzyme assay showed selective topoisomerase IIα inhibition by compound 4h, leading to DNA damage as observed by fluorescent staining. Cell signalling studies showed decreased expression of cell cycle promoting related proteins while apoptotic proteins were upregulated. Interestingly MDA-MB-231 cells showed only cytostatic effects upon treatment with compound 4h due to defective p53 status. Toxicity study using overexpression of dominant-negative mutant p53 in MCF-7 cells (which have wild type functional p53) showed that anticancer potential of compound 4h is positively correlated with p53 expression.


Subject(s)
Antineoplastic Agents/pharmacology , Drug Design , Pyridines/pharmacology , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Apoptosis/drug effects , Cell Proliferation/drug effects , Cell Survival/drug effects , Dose-Response Relationship, Drug , Drug Screening Assays, Antitumor , Humans , Models, Molecular , Molecular Structure , Pyridines/chemical synthesis , Pyridines/chemistry , Structure-Activity Relationship , Tumor Cells, Cultured
4.
Cancer Cell Int ; 21(1): 629, 2021 Nov 27.
Article in English | MEDLINE | ID: mdl-34838007

ABSTRACT

BACKGROUND AND OBJECTIVES: MicroRNA (miRNA) that translocate from the nucleus to mitochondria are referred to as mitochondrial microRNA (mitomiR). Albeit mitomiRs have been shown to modulate gene expression, their functional impact within mitochondria is unknown. The main objective of this study is to investigate whether the mitochondrial genome is regulated by miR present inside the mitochondria. METHODS AND RESULTS: Here, we report mitomiR let-7a regulates mitochondrial transcription in breast cancer cells and reprogram the metabolism accordingly. These effects were mediated through the interaction of let-7a with mtDNA, as studied by RNA pull-down assays, altering the activity of Complex I in a cell line-specific manner. Our study, for the first time, identifies the role of mitomiR (let-7a) in regulating the mitochondrial genome by transcriptional repression and its contribution to regulating mitochondrial metabolism of breast cancer cells. CONCLUSION: These findings uncover a novel mechanism by which mitomiR regulates mitochondrial transcription.

5.
Future Med Chem ; 13(5): 457-485, 2021 03.
Article in English | MEDLINE | ID: mdl-33506699

ABSTRACT

Aim: Keeping in view the side effects associated with clinically used α-glucosidase inhibitors, novel thiazolidinedione-isatin hybrids were synthesized and evaluated by in vitro, in vivo and in silico procedures. Materials & methods: Biological evaluation, cytotoxicity assessment, molecular docking, binding free energy calculations and molecular dynamics studies were performed for hybrids. Results: The most potent inhibitor A-10 (IC50 = 24.73 ± 0.93 µM) was competitive in manner and observed as non-cytotoxic. A-10 possessed higher efficacy than the standard drug (acarbose) during in vivo biological testing. Conclusion: The enzyme inhibitory potential and safety profile of synthetic molecules was recognized after in vitro, in vivo, in silico and cytotoxicity studies. Further structural optimization of A-10 can offer potential hit molecules suitable for future investigations.


Subject(s)
Glycoside Hydrolase Inhibitors/chemistry , Hypoglycemic Agents/chemical synthesis , Isatin/chemistry , Thiazolidinediones/chemistry , Animals , Binding Sites , Cell Line , Cell Survival/drug effects , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/pathology , Glucose Tolerance Test , Glycoside Hydrolase Inhibitors/metabolism , Glycoside Hydrolase Inhibitors/pharmacology , Glycoside Hydrolase Inhibitors/therapeutic use , Half-Life , Humans , Hypoglycemic Agents/metabolism , Hypoglycemic Agents/pharmacology , Hypoglycemic Agents/therapeutic use , Kinetics , Male , Mice , Molecular Docking Simulation , Structure-Activity Relationship , alpha-Glucosidases/chemistry , alpha-Glucosidases/metabolism
6.
Curr Mol Med ; 19(9): 621-631, 2019.
Article in English | MEDLINE | ID: mdl-31340735

ABSTRACT

MicroRNAs [miRNAs] are short, non-coding, single stranded RNA molecules regulating gene expression of their targets at the posttranscriptional level by either degrading mRNA or by inhibiting translation. Previously, miRNAs have been reported to be present inside the mitochondria and these miRNAs have been termed as mito-miRs. Origin of these mito-miRs may either be from mitochondrial genome or import from nucleus. The second class of mito-miRs makes it important to unravel the involvement of miRNAs in crosstalk between nucleus and mitochondria. Since miRNAs are involved in various physiological processes, their deregulation is often associated with disease progression, including cancer. The current review focuses on the involvement of miRNAs in different mitochondrial mediated processes. It also highlights the importance of exploring the interaction of miRNAs with mitochondrial genome, which may lead to the development of small regulatory RNA based therapeutic options.


Subject(s)
Disease Susceptibility , Gene Expression Regulation, Neoplastic , MicroRNAs/genetics , Neoplasms/etiology , RNA, Mitochondrial/genetics , Apoptosis , Combined Modality Therapy , Energy Metabolism , Genetic Predisposition to Disease , Genome, Mitochondrial , Humans , Mitochondrial Proteins/metabolism , Mitophagy , Molecular Targeted Therapy , Neoplasms/metabolism , Neoplasms/pathology , Neoplasms/therapy , Organelle Biogenesis , RNA Transport
8.
Sci Rep ; 8(1): 11926, 2018 08 09.
Article in English | MEDLINE | ID: mdl-30093705

ABSTRACT

Drugs that are already clinically approved or experimentally tested for conditions other than cancer, but are found to possess previously unrecognized cytotoxicity towards malignant cells, may serve as fitting anti-cancer candidates. Methyl N-(6-phenylsulfanyl-1H benzimidazol-2-yl) carbamate [Fenbendazole, FZ], a benzimidazole compound, is a safe and inexpensive anthelmintic drug possessing an efficient anti-proliferative activity. In our earlier work, we reported a potent growth-inhibitory activity of FZ caused partially by impairment of proteasomal function. Here, we show that FZ demonstrates moderate affinity for mammalian tubulin and exerts cytotoxicity to human cancer cells at micromolar concentrations. Simultaneously, it caused mitochondrial translocation of p53 and effectively inhibited glucose uptake, expression of GLUT transporters as well as hexokinase (HK II) - a key glycolytic enzyme that most cancer cells thrive on. It blocked the growth of human xenografts in nu/nu mice model when mice were fed with the drug orally. The results, in conjunction with our earlier data, suggest that FZ is a new microtubule interfering agent that displays anti-neoplastic activity and may be evaluated as a potential therapeutic agent because of its effect on multiple cellular pathways leading to effective elimination of cancer cells.


Subject(s)
Carcinoma, Non-Small-Cell Lung/drug therapy , Cell Physiological Phenomena/drug effects , Fenbendazole/pharmacology , Lung Neoplasms/drug therapy , Tubulin Modulators/pharmacology , Xenograft Model Antitumor Assays/methods , A549 Cells , Animals , Carcinoma, Non-Small-Cell Lung/metabolism , Carcinoma, Non-Small-Cell Lung/pathology , Cell Death/drug effects , Cell Line, Tumor , Female , Glycolysis/drug effects , Hexokinase/metabolism , Humans , Lung Neoplasms/metabolism , Lung Neoplasms/pathology , Mice, Nude
9.
Toxicol Sci ; 165(1): 157-169, 2018 09 01.
Article in English | MEDLINE | ID: mdl-29893964

ABSTRACT

The alarming health issues especially the unusually high number of cancer cases in agriculture community of Bathinda district of Punjab (India) is a serious concern. There is limited knowledge about the role of gene-environment interactions in oncogenesis prevalent in this area. The aim of this study was to evaluate the association of oxidative stress with CYP1A2, CYP2B6, CYP2C9, CYP3A4, and PON1 genetic variation in the pesticide-exposed (occupationally) population of Bathinda district of Punjab (India). This study demonstrated significantly elevated relative risk (RR) of lower antioxidant defense mechanism (Glutathione, Catalase, Superoxide Dismutase, Glutathione peroxidases, and Glutathione Reductase) in occupationally pesticide-exposed group (n = 120) as compared with unexposed group (n = 84) from Bathinda district of Punjab (India). Our data shows pesticide exposure to be a major risk factor leading to increased oxidative stress inside the body. Gas chromatographic analysis revealed the residues of organophosphates (chlorpyriphos, dichlorvos, ethoprophos) and herbicides (atrazine, butachlor, alachlor, metolachlor) in the blood samples of the exposed population. In vitro results showed a dose dependent decrease in cell viability following treatment of pesticides detected in blood samples in hPBMCs and A549 cell line. Genetic variation analysis revealed missense mutations in CYP2B6 (2 mutations), CY3A4 (1 mutation), and CYP2C9 (2 mutations). The observed mutations have been predicted to cause structural and conformation change in protein structure which could result in altered stability. In first of its kind of study, our data reveal oxidative stress and pesticide residue accumulation inside the body to be the major reasons for health concerns in Bathinda district.


Subject(s)
Genetic Predisposition to Disease , Neoplasms/epidemiology , Occupational Exposure/analysis , Oxidative Stress/drug effects , Pesticide Residues/blood , A549 Cells , Cell Survival/drug effects , Cytochrome P-450 CYP2B6/genetics , Cytochrome P-450 CYP2C9/genetics , Cytochrome P-450 CYP3A/genetics , Dose-Response Relationship, Drug , Gene-Environment Interaction , Humans , India , Male , Mutation, Missense , Neoplasms/enzymology , Neoplasms/genetics , Occupational Exposure/adverse effects , Oxidative Stress/genetics , Polymorphism, Genetic , Risk Assessment
10.
Curr Treat Options Oncol ; 19(4): 20, 2018 03 20.
Article in English | MEDLINE | ID: mdl-29556842

ABSTRACT

OPINION STATEMENT: The cells of malignant cancers result in the evolution of cells with stem-like characteristics, commonly known as cancer stem cells (CSCs). Progress of anticancer therapies is severely hampered because of disease relapse mostly in a more aggressive form due to CSCs. These CSCs are more or less like embryonic or tissue stem cells, known for their capacity of self-renewal, exactly recapitulate of the original tumor. Deregulation of key stem cell pathways like Wnt, Hedgehog (Hh), and Notch is attributed towards the rise of CSCs. Recent breakthroughs offer better insights into CSC signaling. Scientists have developed several combinatorial therapies like targeting one/multiple of these CSC pathways. The article summarized various markers used to identify CSCs and discuss major signaling pathways in them. The futuristic probabilities to use CSC therapeutics in clinical development have been discussed. Our views have been highlighted on the future directions for targeting advances in the clinical development.


Subject(s)
Neoplasms/pathology , Neoplastic Stem Cells/pathology , Biomarkers, Tumor/genetics , Humans , Neoplasm Recurrence, Local/pathology , Neoplasms/genetics , Neoplastic Stem Cells/drug effects , Wnt Signaling Pathway/physiology
11.
Bioorg Chem ; 78: 130-140, 2018 08.
Article in English | MEDLINE | ID: mdl-29554587

ABSTRACT

A number of pyrimidine bridged combretastatin derivatives were designed, synthesized and evaluated for anticancer activities against breast cancer (MCF-7) and lung cancer (A549) cell lines using MTT assays. Most of the synthesized compounds displayed good anticancer activity with IC50 values in low micro-molar range. Compounds 4a and 4p were found most potent in the series with IC50 values of 4.67 µM & 3.38 µM and 4.63 µM & 3.71 µM against MCF7 and A549 cancer cell lines, respectively. Biological evaluation of these compounds showed that selective cancer cell toxicity (in vitro using human lung and breast cancer cell lines) might be due to the inhibition of antioxidant enzymes instigating elevated ROS levels which triggers intrinsic apoptotic pathways. These compounds were found nontoxic to the normal human primary cells. Compound 4a, was found to be competitive inhibitor of colchicine and in the tubulin binding assay it showed tubulin polymerization inhibition potential comparable to colchicine. The molecular modeling studies also showed that the synthesized compounds fit well in the colchicine-binding pocket.


Subject(s)
Antineoplastic Agents/pharmacology , Bibenzyls/pharmacology , Pyrimidines/pharmacology , Animals , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Apoptosis/drug effects , Bibenzyls/chemical synthesis , Bibenzyls/chemistry , Cattle , Cell Line, Tumor , Cell Proliferation/drug effects , Colorimetry , Dose-Response Relationship, Drug , Drug Screening Assays, Antitumor , Humans , Models, Molecular , Molecular Structure , Polymerization/drug effects , Pyrimidines/chemistry , Reactive Oxygen Species/antagonists & inhibitors , Reactive Oxygen Species/metabolism , Structure-Activity Relationship , Tubulin/metabolism
12.
Can J Physiol Pharmacol ; 95(10): 1263-1270, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28686848

ABSTRACT

The etiology of cardiac fibrogenesis is quite diverse, but a common feature is the presence of activated fibroblasts. Experimental evidence suggests that a subset of cardiac fibroblasts is derived via transition of vascular endothelial cells into fibroblasts by endothelial-to-mesenchymal transition (EndMT). During EndMT, endothelial cells lose their endothelial characteristics and acquire a mesenchymal phenotype. Molecular mechanisms and the transcriptional mediators controlling EndMT in heart during development or disease remain relatively undefined. Myocardin-related transcription factor A facilitates the transcription of cytoskeletal genes by serum response factor during fibrosis; therefore, its specific role in cardiac EndMT might be of importance. Activation of activating transcription factor 3 (ATF-3) during cardiac EndMT is speculative, since ATF-3 responds to a transforming growth factor ß (TGF-ß) stimulus and controls the expression of the primary epithelial-to-mesenchymal transition markers Snail, Slug, and Twist. Although the role of TGF-ß in EndMT-mediated cardiac fibrosis has been established, targeting of the TGF-ß ligand has not proven to be a viable anti-fibrotic strategy owing to the broad functional importance of this ligand. Thus, targeting of downstream transcriptional mediators may be a useful therapeutic approach in attenuating cardiac fibrosis. Here, we discuss some of the transcription factors that may regulate EndMT-mediated cardiac fibrosis and their involvement in type 2 diabetes.


Subject(s)
Activating Transcription Factor 3/metabolism , Cardiomyopathies/metabolism , Endothelial Cells/metabolism , Epithelial-Mesenchymal Transition , Fibroblasts/metabolism , Myocardium/metabolism , Trans-Activators/metabolism , Activating Transcription Factor 3/genetics , Animals , Cardiomyopathies/drug therapy , Cardiomyopathies/genetics , Cardiomyopathies/pathology , Diabetes Mellitus, Type 2/genetics , Diabetes Mellitus, Type 2/metabolism , Diabetic Cardiomyopathies/genetics , Diabetic Cardiomyopathies/metabolism , Diabetic Cardiomyopathies/pathology , Endothelial Cells/drug effects , Endothelial Cells/pathology , Epithelial-Mesenchymal Transition/drug effects , Fibroblasts/drug effects , Fibroblasts/pathology , Fibrosis , Gene Expression Regulation , Humans , Myocardium/pathology , Phenotype , Signal Transduction , Trans-Activators/genetics
13.
Mol Cell Biochem ; 417(1-2): 191-203, 2016 Jun.
Article in English | MEDLINE | ID: mdl-27221738

ABSTRACT

p53-p21 pathway mediates cardiomyocyte hypertrophy and apoptosis and is upregulated in diabetic cardiomyopathy (DbCM). We investigated role of microRNAs in regulating p53-p21 pathway in high glucose (HG)-induced cardiomyocyte hypertrophy and apoptosis. miR-30c and miR-181a were identified to target p53. Cardiac expression of microRNAs was measured in diabetic patients, diabetic rats, and in HG-treated cardiomyocytes. Effect of microRNAs over-expression and inhibition on HG-induced cardiomyocyte hypertrophy and apoptosis was examined. Myocardial expression of p53 and p21 genes was increased and expression of miR-30c and miR-181a was significantly decreased in diabetic patients, DbCM rats, and in HG-treated cardiomyocytes. Luciferase assay confirmed p53 as target of miR-30c and miR-181a. Over-expression of miR-30c or miR-181a decreased expression of p53, p21, ANP, cardiomyocyte cell size, and apoptosis in HG-treated cardiomyocytes. Concurrent over-expression of these microRNAs resulted in greater decrease in cardiomyocyte hypertrophy and apoptosis, suggesting a synergistic effect of these microRNAs. Our results suggest that dysregulation of miR-30c and miR-181a may be involved in upregulation of p53-p21 pathway in DbCM.


Subject(s)
Cyclin-Dependent Kinase Inhibitor p21/metabolism , Diabetes Mellitus, Experimental/metabolism , Diabetic Cardiomyopathies/metabolism , MicroRNAs/metabolism , Myocytes, Cardiac/metabolism , Tumor Suppressor Protein p53/metabolism , Animals , Diabetes Mellitus, Experimental/pathology , Diabetic Cardiomyopathies/pathology , Male , Myocytes, Cardiac/pathology , Rats , Rats, Wistar
14.
PLoS One ; 7(7): e40469, 2012.
Article in English | MEDLINE | ID: mdl-22792341

ABSTRACT

BACKGROUND: The objective of this study was to establish the buffalo mammary epithelial cell line (BuMEC) and characterize its mammary specific functions. METHODOLOGY: Buffalo mammary tissue collected from the slaughter house was processed enzymatically to obtain a heterogenous population of cells containing both epithelial and fibroblasts cells. Epithelial cells were purified by selective trypsinization and were grown in a plastic substratum. The purified mammary epithelial cells (MECs) after several passages were characterized for mammary specific functions by immunocytochemistry, RT-PCR and western blot. PRINCIPAL FINDINGS: The established buffalo mammary epithelial cell line (BuMEC) exhibited epithelial cell characteristics by immunostaining positively with cytokeratin 18 and negatively with vimentin. The BuMEC maintained the characteristics of its functional differentiation by expression of ß-casein, κ-casein, butyrophilin and lactoferrin. BuMEC had normal growth properties and maintained diploid chromosome number (2n = 50) before and after cryopreservation. A spontaneously immortalized buffalo mammary epithelial cell line was established after 20 passages and was continuously subcultured for more than 60 passages without senescence. CONCLUSIONS: We have established a buffalo mammary epithelial cell line that can be used as a model system for studying mammary gland functions.


Subject(s)
Buffaloes , Epithelial Cells/physiology , Mammary Glands, Animal/cytology , Animals , Cell Culture Techniques , Cell Proliferation , Cell Shape , Cells, Cultured , Cellular Senescence , Chromosomes, Mammalian/metabolism , Collagen/metabolism , Culture Media , Cytoskeletal Proteins/metabolism , Epithelial Cells/cytology , Epithelial Cells/metabolism , Female , Karyotype , Milk Proteins/genetics , Milk Proteins/metabolism , Transcriptome , beta-Galactosidase/metabolism
15.
J Biol Chem ; 287(36): 30625-40, 2012 Aug 31.
Article in English | MEDLINE | ID: mdl-22745125

ABSTRACT

In recent years, there has been a great deal of interest in proteasome inhibitors as a novel class of anticancer drugs. We report that fenbendazole (FZ) (methyl N-(6-phenylsulfanyl-1H-benzimidazol-2-yl)carbamate) exhibits a potent growth-inhibitory activity against cancer cell lines but not normal cells. We show here, using fluorogenic substrates, that FZ treatment leads to the inhibition of proteasomal activity in the cells. Succinyl-Leu-Leu-Val-Tyr-methylcoumarinamide (MCA), benzyloxycarbonyl-Leu-Leu-Glu-7-amido-4-MCA, and t-butoxycarbonyl-Gln-Ala-Arg-7-amido-4-MCA fluorescent derivatives were used to assess chymotrypsin-like, post-glutamyl peptidyl-hydrolyzing, and trypsin-like protease activities, respectively. Non-small cell lung cancer cells transiently transfected with an expression plasmid encoding pd1EGFP and treated with FZ showed an accumulation of the green fluorescent protein in the cells due to an increase in its half-life. A number of apoptosis regulatory proteins that are normally degraded by the ubiquitin-proteasome pathway like cyclins, p53, and IκBα were found to be accumulated in FZ-treated cells. In addition, FZ induced distinct ER stress-associated genes like GRP78, GADD153, ATF3, IRE1α, and NOXA in these cells. Thus, treatment of human NSCLC cells with fenbendazole induced endoplasmic reticulum stress, reactive oxygen species production, decreased mitochondrial membrane potential, and cytochrome c release that eventually led to cancer cell death. This is the first report to demonstrate the inhibition of proteasome function and induction of endoplasmic reticulum stress/reactive oxygen species-dependent apoptosis in human lung cancer cell lines by fenbendazole, which may represent a new class of anticancer agents showing selective toxicity against cancer cells.


Subject(s)
Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Cytotoxins/pharmacology , Fenbendazole/pharmacology , Neoplasms/drug therapy , Proteasome Endopeptidase Complex/metabolism , Ubiquitin/metabolism , Activating Transcription Factor 3/metabolism , Antinematodal Agents/pharmacology , Cell Line, Tumor , Cytochromes c/metabolism , Endoplasmic Reticulum Chaperone BiP , Endoribonucleases/metabolism , Heat-Shock Proteins/metabolism , Humans , I-kappa B Proteins/metabolism , Membrane Potentials/drug effects , NF-KappaB Inhibitor alpha , Neoplasms/metabolism , Neoplasms/pathology , Protein Serine-Threonine Kinases/metabolism , Proto-Oncogene Proteins c-bcl-2/metabolism , Transcription Factor CHOP/metabolism , Tumor Suppressor Protein p53/metabolism , Ubiquitination/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...